Drug-drug interactions

  • Eur J Pharm Sci. 2021;165:105932. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions. Lang J, Vincent L, Chenel M, Ogungbenro K, Galetin A. PubMed
  • Eur J Pharm Sci. 2021;165:105951. Pre-incubation with OATP1B1 and OATP1B3 inhibitors potentiates inhibitory effects in physiologically relevant sandwich-cultured primary human hepatocytes. Farasyn T, Pahwa S, Xu C, Yue W. PubMed

Liver imaging

  • Mol Pharm. 2021;18:2997-3009. Physiologically based pharmacokinetic modeling of transporter-mediated hepatic disposition of imaging biomarker Gadoxetate in rats. Scotcher D, Melillo N, Tadimalla S, Darwich AS, Ziemian S, Ogungbenro K, Schütz G, Sourbron S, Galetin A. PubMed
  • J Nucl Med. 2021;62:934-940. 11C-Sorafenib and 15O-H2O PET for early evaluation of Sorafenib therapy. Mammatas LH, Yaqub M, Hendrikse NH, Hoekstra OS, Honeywell RJ, Schuit RC, Meijerink M, Schwarte LA, Peters GJ, Verheul HMW, Lammertsma AA, Menke-van der Houven van Oordt CW. PubMed
  • Pharmaceutics. 2021 Jun;13:918. Imaging-Based Characterization of a Slco2b1(-/-) mouse model using [11C]Erlotinib and [99mTc]Mebrofenin as probe substrates. Marie S, Hernández-Lozano I, Breuil L, Truillet C, Hu S, Sparreboom A, Tournier N, Langer O. PubMed

Quantitative proteomics

  • Clin Pharmacol Ther. 2021;In press. Quantitative proteomic map of enzymes and transporters in the human kidney: Stepping closer to mechanistic kidney models to define local kinetics. Al-Majdoub ZM, Scotcher D, Achour B, Barber J, Galetin A, Rostami-Hodjegan A. PubMed

Hepatocyte spheroids

  • Drug Metab Dispos. 2021;In press. Primary human hepatocyte spheroids as an in vitro tool for investigating drug compounds with low clearance. Riede J, Wollmann BM, Molden E, Ingelman-Sundberg M. PubMed

HEK293 cell ± human plasma

  • Drug Metab Dispos. 2021;49:530-539. Improving the translation of Organic Anion Transporting Polypeptide substrates using HEK293 cell data in the presence and absence of human plasma via Physiologically Based Pharmacokinetic modeling. Bowman CM, Chen B, Cheong J, Liu L, Chen Y, Mao J. PubMed

Scaling factors

  • Drug Metab Dispos. 2021;49:563-571. Hepatic scaling factors for in vitro-in vivo extrapolation of metabolic drug clearance in patients with colorectal cancer with liver metastasis. Vasilogianni AM, Achour B, Scotcher D, Peters SA, Al-Majdoub ZM, Barber J, Rostami-Hodjegan A. PubMed

Transporters and statins

  • Clin Pharmacol Ther. 2021;110:733-740.  Effect of SLCO1B1 T521C on statin-related myotoxicity with use of Lovastatin and Atorvastatin.Lu B, Sun L, Seraydarian M, Hoffmann TJ, Medina MW, Risch N, Iribarren C, Krauss RM, Oni-Orisan A.  PubMed
  • Drug Metab Dispos. 2021;In press. Comparative hepatic and intestinal efflux transport of statins. Deng F, Tuomi SK, Neuvonen M, Hirvensalo P, Kulju S, Wenzel C, Oswald S, Filppula AM, Niemi M. PubMed

Transporters and prolonged cultures of hepatocytes

  • Drug Metab Dispos. 2021;In press. Messenger RNA expression of albumin, transferrin, transthyretin, asialoglycoprotein receptor, P450 isoform, uptake transporter and efflux transporter genes as a function of culture duration in prolonged cultured cryopreserved human hepatocytes from 7 donors as collagen-matrigel sandwich cultures: Evidence for redifferentiation upon prolonged culturing. Yang Q, Li AP. PubMed

OATP1B1 and SN-38

  • Cancer Chemother Pharmacol. 2021;88:543-553. Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure. Tsuboya A, Kubota Y, Ishida H, Ohkuma R, Ishiguro T, Hirasawa Y, Ariizumi H, Tsunoda T, Sasaki Y, Matsumoto N, Kondo Y, Tomoda Y, Kusuhara H, Fujita KI. PubMed